Adherence in Glaucoma: Objective Measurements of Once-Daily and Adjunctive Medication Use

American Journal of Ophthalmology

Volumn 144, Issue 4, 2007, Pages

  Robin, Alan L ^a,b,c   Novack, Gary D ^d   Covert, David W ^e   Crockett, R Stephens ^f   Marcic, Tania S ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c Mid Atlantic Glaucoma Specialists   (United States)

^d PHARMALOGIC DEVELOPMENT INC   (United States)

^e ALCON RESEARCH LTD   (United States)

^f DATA Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; PROSTAGLANDIN DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG MONITORING; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICATION ERROR; MONOTHERAPY; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL;

EID: 34548774065     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2007.06.012     Document Type: Article

References (28)

1. DiMatteo M.R. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 42 (2004) 200-209
2. Cramer J.A., Mattson R.H., Prevey M.L., et al. How often is medication taken as prescribed?. A novel assessment technique. JAMA 261 (1989) 3273-3277
3. Waterhouse D.M., Calzone K.A., Mele C., and Brenner D.E. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 11 (1993) 1189-1197
4. Blackwell B. Treatment adherence. Br J Psychiatry 129 (1976) 513-531
5. Patel S.C., and Spaeth G.L. Compliance in patients prescribed eye drops for glaucoma. Ophthalmic Surg 26 (1995) 233-236
6. Kass M.A., Heuer D.K., Higginbotham E.J., et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120 (2002) 701-713
7. Lichter P.R., Musch D.C., Gillespie B.W., et al. Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery. Ophthalmology 108 (2001) 1943-1953
8. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130 (2000) 429-440
9. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 126 (1998) 498-505
10. Kass M.A., Meltzer D.W., Gordon M., et al. Compliance with topical pilocarpine treatment. Am J Ophthalmol 101 (1986) 515-523
11. Kass M.A., Gordon M., Morley R.E., et al. Compliance with topical timolol treatment. Am J Ophthalmol 103 (1987) 188-193
12. ™ dosing aid accurately records when drops are taken. Am J Ophthalmol 143 (2007) 699-701
13. Urquhart J. How much compliance is enough?. Pharm Res 13 (1996) 10-11
14. Urquhart J. Pharmacodynamics of variable patient compliance: implications for pharmaceutical value. Adv Drug Deliv Rev 33 (1998) 207-219
15. Vrijens B., Gross R., and Urquhart J. The odds that clinically unrecognized poor or partial adherence confuses population pharmacokinetic/pharmacodynamic analyses. Basic Clin Pharmacol Toxicol 96 (2005) 225-227
16. Urquhart J. Erratic patient compliance with prescribed drug regimens: target for drug delivery systems. Clin Pharm Ther 67 (2000) 331-334
17. Tan D.T.H., Lam D.S., Chua W.H., et al. One-year multicenter, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia. Ophthalmology 112 (2005) 84-91
18. Siatkowski R.M., Cotter S., Miller J.M., et al. Safety and efficacy of 2% pirenzepine ophthalmic gel in children with myopia: a 1-year, multicenter, double-masked, placebo-controlled parallel study. Arch Ophthalmol 122 (2004) 1667-1674
19. Robin A.L., and Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?. Ophthalmology 112 (2005) 863-868
20. Cramer J.A. Consequences of intermittent treatment for hypertension: the case for medication compliance and persistence. Am J Manag Care 4 (1998) 1563-1568
21. Vrijens B., Belmans A., Matthys K., and Lesaffre E. Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiol Drug Saf 15 (2005) 115-121
22. Wilensky J., Fiscella R.G., Carlson A.M., et al. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. Am J Ophthalmol 141 (2006) S28-S33
23. Feinstein A.R. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med 150 (1990) 1377-1378
24. Boden C., Sit A., and Weinreb R.N. Accuracy of an electronic monitoring and reminder device for use with travoprost eye drops. J Glaucoma 15 (2006) 30-34
25. ™ dosing aid accurately records when drops are taken. Am J Ophthalmol 143 (2007) 699-701
26. Urquhart J. Patient non-compliance with drug regimens: measurement, clinical correlates, economic impact. Eur Heart J 17 (1996) 8-15
27. Vrijens B., Belmans A., Matthys K., et al. Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiol Drug Saf 15 (2006) 115-121
28. Covert D., and Robin A.L. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost. Curr Med Res Opin 22 (2006) 971-976